Ozmosi | Sodium polystyrene sulfonate Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Sodium polystyrene sulfonate

Alternative Names: sodium polystyrene sulfonate, sps, kalexate, kionex, kayexalate
Clinical Status: Inactive
Latest Update: 2026-01-16
Latest Update Note: News Article

Product Description

Sodium polystyrene sulfonate is used to treat high levels of potassium in the blood, also called hyperkalemia. (Sourced from: https://www.mayoclinic.org/drugs-supplements/sodium-polystyrene-sulfonate-oral-route-route-not-applicable/description/drg-20073487)

Mechanisms of Action: Potassium Reducer

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral, Intramuscular

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Hong Kong | India | Ireland | Italy | Malaysia | Morocco | New Zealand | Pakistan | Taiwan | Tunisia | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated